Italian Anderson Fabry Disease Cardiovascular Registry

Brief summary (registry, in English)

The RICMAF Study is an observational, multicenter, non-pharmacological study conducted in Italy. Although Anderson-Fabry Disease (AFD) is rare, it is likely underdiagnosed due to its nonspecific symptoms, leading to delays in proper treatment. The RICMAF Study aims to improve understanding of AFD, especially its cardiac manifestations, which are a major cause of mortality. By gathering data from a large, nationwide patient registry, this study seeks to answer key questions about AFD's clinical course and improve patient outcomes. The primary goals of the RICMAF Study are: * To analyze the clinical profile, prevalence, and incidence of AFD, along with patients' family history and disease progression. * To identify early markers of cardiac involvement and predictors of cardiovascular complications to personalize care. * To investigate the relationship between genetic mutations, clinical presentation, and prognosis. * To find early indicators of organ damage through laboratory and imaging tests. All patients diagnosed with AFD following international guidelines are eligible.

What you commit to

• Study type: Observational
• Planned participants: 800
• From 26 Jan 2022 to the primary completion date, 31 Jan 2031
• 54 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (54)

Sites in registry order. Save your city in your profile to sort them by distance.